By May of 2022, the phase 3 SKYSCRAPER-01 study (NCT04294810) evaluating the addition of tiragolumab (anti-TIGIT) to atezolizumab (anti-PD-L1) as first-line treatment for people with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet its co-primary end point of progression-free survival (PFS), according to Roche (https://bit.ly/37EbDJX). Here, CD274 is linked to non-small cell lung carcinoma.